- $581.07m
- $528.01m
- $52.23m
Brief: Brainsway Reports First Quarter 2023 Financial Results And Operational Highlights
Brief: Brainsway Announces Appointment Of Ami Boehm As New Chairman
Brief: Brainsway Announces Appointment Of Hadar Levy As CEO
Brief: Brainsway Announces Extended Private Insurance Coverage In Washington State For The Treatment Of Ocd And Depression Utilizing Deep Tms™
Brief: Brainsway Resolves Neuronetics Litigation
Brief: Brainsway Reports Open Market Stock Purchases By Two Board Members
Brief: Brainsway Reports Q3 Financial Results And Operational Highlights
Brief: Brainsway Appoints Dr. Colleen A. Hanlon As Vice President Of Medical Affairs
Brief: Brainsway And Nocd Launch Collaboration To Increase Awareness Of Ocd Treatments
Brief: BrainsWay Announces Private Insurance Coverage From Cigna Corp
Refinitiv Newscasts - Trading at Noon: Rate fever as stocks and bonds slump
Brainsway shares rise after FDA clears depression treatment device
Brief: BrainsWay Receives New FDA Clearance For Treating Depression And Anxious Depression
Brief: Brainsway Reports Q2 Revenue Of $8 Mln, Up 14%
Brief: Brainsway Ltd Says Israeli Ministry Of Health Has Approved Coverage Applicable To Its Deep TMS System For Treatment Of Depression
Brief: Brainsway Announces Positive OCD Coverage Policy From Blue Cross Blue Shield (BCBS) Licensee Highmark BCBS For Deep TMS
Brief: Brainsway Reports First Quarter 2022 Financial Results And Operational Highlights
Brief: Brainsway Appoints Joachim Seidel As VP Of Corporate Development, Strategy
Brief: Brainsway Reports Q4 Revenue Of $8.5 Mln